RESUMO
The patient was a 75-year-old man who had undergone potentially curative surgery for Stage â ¢b rectal cancer followed by resection of liver metastases. Two years after the resection of liver metastases, lung and remnant liver metastases were found. He received chemotherapy for unresectable metastatic tumors. Based on the findings of molecular and pathological examinations(RAS: wild type; BRAF: wild type; MSI: negative; HER2: negative), the following chemotherapy regimens were administered: first-line, FOLFIRI plus panitumumab(PANI); second-line, mFOLFOX6; third-line, trifluridine/tipiracil; fourth- line, regorafenib. After fourth-line treatment, he was judged to have disease progression due to the increase in his lung and liver metastases and the elevation of tumor markers. All standard regimens were refractory, but the Eastern Cooperative Oncology Group performance status was zero and a liquid biopsy for RAS still showed wild type. Therefore, rechallenge therapy with anti-epidermal growth factor receptor(EGFR)drugs, cetuximab(CET)and irinotecan(IRI), was administered 13 months after the final course of FOLFIRI plus PANI treatment. After 4 courses of CET plus IRI, the size of the 2 metastatic tumors markedly decreased and his tumor marker levels normalized.
Assuntos
Neoplasias Hepáticas , Neoplasias Retais , Idoso , Humanos , Masculino , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Cetuximab , Receptores ErbB , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/cirurgia , Neoplasias Hepáticas/secundário , Recidiva Local de Neoplasia/tratamento farmacológico , Receptores de Fatores de Crescimento/uso terapêutico , Neoplasias Retais/tratamento farmacológico , Neoplasias Retais/cirurgia , Neoplasias Retais/patologiaRESUMO
Background: Breast cancer (BC) has the highest morbidity rate and the second-highest mortality rate of all cancers among women. Recently, multi-cancer genome profiling (multi-CGP) tests have become clinically available. In this study, we aimed to clarify the significance of multi-CGP testing of BC by using the large clinical dataset from The Center for Cancer Genomics and Advanced Therapeutics (C-CAT) profiling database in Japan. Materials and Methods: A total of 3744 BC cases were extracted from the C-CAT database, which enrolled 60,250 patients between June 2019 and October 2023. Of the 3744 BC cases, a total of 3326 cases for which the C-CAT included information on ER, PR, and HER2 status were classified into four subtypes, including TNBC, HR+/HER2-, HR+/HER2+, and HR-/HER2+. Comparisons between groups were performed by the χ2 test or Fisher's exact test using EZR. Kaplan-Meier curves were created using the log-rank test. Results: Of all 3326 cases analyzed, 1114 (33.5%) were TNBC cases, HR+/HER2- accounted for 1787 cases (53.7%), HR+/HER2+ for 260 cases (7.8%), and HR-/HER2+ for 165 cases (5.0%). Genetic abnormalities were most frequently detected in TP53 (58.0%), PIK3CA (35.5%), MYC (18.7%), FGF19 (15.5%), and GATA3 (15.1%) across all BCs. The rate of TMB-High was 12.3%, and the rate of MSI-High was 0.3%, in all BC cases. Therapeutic drugs were proposed for patients with mutations in six genes: PIK3CA, ERBB2, PTEN, FGFR1, ESR1, and AKT1. The prognoses of HR+/HER2- cases were significantly (p = 0.044) better in the treated group than in the untreated group. Conclusions: These findings suggest that cancer gene panel testing is useful for HR+/HER2- cases.
Assuntos
Neoplasias da Mama , Receptor ErbB-2 , Humanos , Feminino , Japão/epidemiologia , Pessoa de Meia-Idade , Neoplasias da Mama/genética , Receptor ErbB-2/genética , Idoso , Adulto , Estudos Retrospectivos , Biomarcadores Tumorais/genética , Receptores de Estrogênio/genética , Receptores de Estrogênio/metabolismo , Receptores de Progesterona/genética , Receptores de Progesterona/metabolismo , Idoso de 80 Anos ou mais , Prognóstico , Mutação , Perfilação da Expressão Gênica/métodos , Classe I de Fosfatidilinositol 3-Quinases/genéticaRESUMO
Background: Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS), a hereditary gastric polyposis syndrome that presents with fundic gastric polyposis, is associated with an increased risk of gastric adenocarcinoma. The four patterns of point mutation in the adenomatous polyposis coli (APC) promoter 1B region have been identified as the cause of GAPPS. GAPPS was first reported in 2012, and only 33 families with GAPPS have been reported worldwide to date. Therefore, the clinical management for GAPPS are still controversial. We herein report two unrelated GAPPS families with the same point mutation site. Case Description: Total seven patients of two families had >100 carpeting polyps in the gastric body and fundus, and one of them (69-year-old female) had gastric adenocarcinoma. As a result of germline analysis, both families harbored a point mutation (c.-192A>G) in APC promoter 1B region, previously reported in only one family. Three of seven patients underwent total gastrectomy, and others were followed-up with regular esophagogastroduodenoscopy (EGD) and biopsy every 6 months. To summarize the reported cases, total 42 patients of 35 families have developed gastric adenocarcinoma. Conclusions: This report may contribute to determining the appropriate guidelines for the clinical practice of GAPPS. When EGD reveals gastric polyposis localized to the gastric body and fundus, it is important to obtain a detailed family history and perform germline mutational analysis. And more, point mutation type of our family cases was a rare pattern, suggested that c.-192A>G pattern might be a pathogenic variant.